new version V2017

insulin secretagogues peptides (incretins)
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

albiglutide
Seino, 2009albiglutideplacebo Exploratory NegativeNCT00530309
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET) Exploratory SuggestingNCT00518115
Rosenstock (30 mg every two weeks), 2009albiglutide biweeklyplacebo (add on MET)SuggestingNCT00518115
HARMONY 7 (114179) ongoing albiglutideliraglutide - NCT01128894
exenatide
Exenatide Trial 10749exenatide before lunch and dinnerexenatide before breakfast and dinner Risk of bias -
NCT00360334exenatideglargineNegativeNCT00360334
Trial 8078exenatide other dosesinsulin glargine (add on MET/SU) -
NCT00085969exenatide other dosesplacebo Exploratory - NCT00085969
phase 2 exenatide once monthlyexenatide once monthlyweekly exenatide -
Fineman, 2003exenatide other dosesplacebo (add on MER+/-SU) Exploratory -
Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)Negative NCT00039026
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)Negative
Poon, 2005exenatide other dosesplacebo Exploratory - NCT00044694
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET) Low risk of bias Negative NCT00039013
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)SuggestingNCT00039013
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET) Low risk of bias Suggesting NCT00035984
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET) Low risk of bias Negative NCT00035984
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET) Risk of bias Negative NCT00099333
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET) Exploratory Suggesting NCT00099619
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+MET Risk of bias Negative NCT00082407
Kim, 2007exenatide weeklyplacebo (add on MET) Exploratory NegativeNCT00103935
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)Suggesting NCT00099320
Zinman 20µg/j A MODIFIER, 2007exenatide 20µg/dplacebo (add on TZD+/-MET) -
Moretto (DOUBLONS avec druker), 2008exenatide other dosesplaceboNegativeNCT00381342
H8O-MC-GWBJ, 9698, 20µg/d, 2008exenatide 20µg/dplacebo Low risk of bias -
H8O-MC-GWBJ, 9698, 10µg/d, 2008exenatide 10µg/dplacebo -
DeFronzo, 2008exenatide 20µg/dsitagliptin (add on MET) Exploratory - NCT00477581
Drucker, 2008exenatide 20µg/dweekly exenatide - NCT00308139
Bergenstal (once daily), 2009exenatide 20µg/dBIAsp 30 daily Risk of bias -
Bergenstal (twice daily), 2009exenatide 20µg/dBIAsp 30 twice daily Risk of bias Negative
HEELA (Davies), 2009exenatide other dosesglargine -
Bunck, 2009exenatide 20µg/dinsulin glargine (add on MET) Exploratory - NCT00097500
LEAD 6 (Buse) exe vs lira, 2009exenatide 10µg twice dailyliraglutide 1.8mg -
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU) Low risk of bias Suggesting NCT00324363
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD) Exploratory Negative
Derosa, 2010exenatide 20µgglibenclamideNegative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargine Risk of bias Suggesting NCT00641056
DURATION-2 (Bergenstal) (vs pioglitazone), 2010exenatide weeklypioglitazoneSuggestingNCT00637273
Apovian, 2010exenatide 20µg/dplaceboNegative
Liutkus, 2010exenatideplaceboNegative
Gill, 2010exenatide 10µg/dplacebo add on MET+/-TZD Exploratory Negative
DeFronzo (EXE vs ROSI), 2010exenatide 20µg/drosiglitazone add on MET Exploratory Negative
DURATION-2 (Bergenstal) (vs sitagliptin), 2010exenatide weeklysitagliptin Exploratory SuggestingNCT00637273
Buse, 2011exenatide 20µg/dplacebo (add on insulin) Low risk of bias Negative NCT00765817
H8O-MC-GWDE ongoing exenatide weeklyliraglutide - NCT01029886
liraglutide
NN2211-1333liraglutide other doses -
NN2211-1796liraglutide other dosesplacebo (add on MET) - NCT00614120
Madsbad (vs Glimepiride), 2004liraglutide other dosesglimepiride Exploratory Suggesting
Madsbad (vs placebo), 2004liraglutide other dosesplaceboNegative
Harder, 2004liraglutide other dosesplacebo Exploratory -
Feinglos, 2005liraglutide other dosesmetformin Exploratory Negative
NN2211-1571 (Vilsbøll), 2007liraglutide other dosesplacebo Exploratory NegativeNCT00154401
Seino, 2008liraglutide other dosesplacebo Exploratory NegativeNCT00154414
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SU Risk of bias Suggesting NCT00518882
LEAD-3 mono 1.2mg (Garber), 2009liraglutide 1.2mgglimepiride Low risk of bias Negative NCT00294723
LEAD-3 mono 1.8mg (Garber), 2009liraglutide 1.8mgglimepiride Low risk of bias Negative NCT00294723
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009liraglutide 1.2mgglimepiride (add on MET) Low risk of bias NegativeNCT00318461
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NegativeNCT00318461
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET) Risk of bias Negative NCT00331851
LEAD 1 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgNegative
LEAD 2 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgNegative
LEAD 4 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgNegative
LEAD-2 (Nauck) (1.2mg vs placebo), 2009liraglutide 1.2mgplacebo (add on MET)Suggesting NCT00318461
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)SuggestingNCT00318461
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU) Low risk of bias Suggesting NCT00318422
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)SuggestingNCT00318422
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)Suggesting NCT00331851
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-1 SU (1.2 vs rosiglitazone), 2009liraglutide 1.2mgrosiflitazoneSuggesting
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU) Low risk of bias SuggestingNCT00318422
Seino, 2010liraglutide other dosesglibenclamide Low risk of bias NegativeNCT00393718
Pratley (1.8 vs 1.2), 2010liraglutide 1.8mgliraglutide 1.2mgNegative
Kaku 0.6mg, 2010liraglutide other dosesplaceboSuggesting
Kaku 0.9mg, 2010liraglutide other dosesplacebo (on top SU)Suggesting
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptin Risk of bias Suggesting NCT00700817
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptin Low risk of bias Suggesting NCT00700817
LEADER, 2016liraglutideplacebo Exploratory ConclusiveNCT01179048
EAGLE ongoing liraglutide other dosesinsulin glargine - NCT01117350
LIBRA ongoing liraglutide other dosesplacebo - NCT01270789
NN2211-1800 ongoing liraglutide other dosesplacebo - NCT00943501
NCT00978393 ongoing liraglutide other dosesplacebo - NCT00978393
NN2211-1799 ongoing liraglutide other dosesplacebo - NCT00620282
NN2211-3619 ongoing liraglutide other dosesplacebo - NCT01206101
NN8022-1923 ongoing liraglutide other dosesplacebo - NCT00781937
NN8022-1922 ongoing liraglutide other dosesplacebo - NCT01272232
NCT01234649 ongoing liraglutide other dosesplacebo (add on MET) - NCT01234649
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU) - NCT00395746
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET) - NCT01296412
lixisenatide
GETGOAL-Llixisenatideplacebo (add on basal insulin) - NCT00715624
Ratner DRI6012, 2010lixisenatideplacebo (add on MET) Exploratory - NCT00299871
GETGOAL-MONO Japan LTS ongoing lixisenatidecontrol - NCT00905255
GetGoal-X ongoing lixisenatideexenatide Exploratory - NCT00707031
ELIXA (EFC11319) ongoing lixisenatideplacebo - NCT01147250
GETGOAL-MONO ongoing lixisenatideplacebo - NCT00688701
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin) - NCT00975286
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin) - NCT00866658
GETGOAL-F1 ongoing lixisenatideplacebo (add on MET) - NCT00763451
GETGOAL-M ongoing lixisenatideplacebo (add on MET) - NCT00712673
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU) - NCT01169779
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET) - NCT00713830
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET) - NCT00763815
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET) - NCT00976937
taspoglutide
Nauck 10 once weekly vs PBO, 2009taspoglutide 10mg once weeklyplacebo Exploratory SuggestingNCT00423501
Nauck 20 once weekly vs PBO, 2009taspoglutide 20mg once weeklyplaceboSuggesting
Nauck 20 every 2 weeks vs PBO, 2009taspoglutide 20mg once every 2 weeksplaceboSuggesting
Ratner (20mg once weekly), 2010taspoglutideplacebo (add on MET) Exploratory SuggestingNCT00460941
BC21625 ongoing taspoglutideexenatide - NCT00717457
ZC22565 ongoing taspoglutideinsulin glargine - NCT01051011
BC20965 ongoing taspoglutideinsulin glargine (add on MET) - NCT00755287
BC21893 ongoing taspoglutidepioglitazone - NCT00909597
BC20750 ongoing taspoglutideplacebo - NCT00744926
BC21713 (vs placebo) ongoing taspoglutideplacebo - NCT00754988
BC20963 ongoing taspoglutideplacebo - NCT00744367
BP21572 ongoing taspoglutideplacebo - NCT00809705
BC22092 ongoing taspoglutideplacebo (add on MET) - NCT00823992
NC25113 ongoing taspoglutideplacebo add on standard treatment - NCT01018173



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons